145 related articles for article (PubMed ID: 32873053)
1. Sex, Drugs, and Adverse Drug Reactions: Sex Differences in Laboratory Monitoring Outcomes After Initiation of Renin-Angiotensin-Aldosterone-System Inhibition Therapy.
Dumanski SM; Ahmed SB
Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e007045. PubMed ID: 32873053
[No Abstract] [Full Text] [Related]
2. Gastrointestinal potassium binding-more than just lowering serum [K(+)]: patiromer, potassium balance, and the renin angiotensin aldosterone axis.
Emmett M; Mehta A
Kidney Int; 2016 Sep; 90(3):484-6. PubMed ID: 27521112
[TBL] [Abstract][Full Text] [Related]
3. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
4. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
5. Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology.
Mochel JP; Fink M; Peyrou M; Desevaux C; Deurinck M; Giraudel JM; Danhof M
Chronobiol Int; 2013 Nov; 30(9):1144-59. PubMed ID: 23931032
[TBL] [Abstract][Full Text] [Related]
6. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors.
Coppens R; Yang J; Ghosh S; Gill J; Chambers C; Easaw JC
J Oncol Pharm Pract; 2019 Sep; 25(6):1366-1373. PubMed ID: 30124122
[TBL] [Abstract][Full Text] [Related]
8. The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension.
Liu Y; Lin Y; Zhang MM; Li XH; Liu YY; Zhao J; Shi L
BMC Cardiovasc Disord; 2020 Jun; 20(1):296. PubMed ID: 32546130
[TBL] [Abstract][Full Text] [Related]
9. Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.
Chrysant SG; Chrysant GS
Curr Hypertens Rep; 2015 Jan; 17(1):511. PubMed ID: 25447989
[TBL] [Abstract][Full Text] [Related]
10. Role of the renin-angiotensin system in kidney development and programming of adult blood pressure.
Almeida LF; Tofteng SS; Madsen K; Jensen BL
Clin Sci (Lond); 2020 Mar; 134(6):641-656. PubMed ID: 32219345
[TBL] [Abstract][Full Text] [Related]
11. THE ROLE OF THE RENIN-ANGIOTENSIN SYSTEM IN BLOOD PRESSURE REGULATION AND KIDNEY FUNCTION.
GROSS F; SCHAECHTELIN G; BRUNNER H; PETERS G
Can Med Assoc J; 1964 Jan; 90(4):258-62. PubMed ID: 14111731
[No Abstract] [Full Text] [Related]
12. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
14. [REGULATION OF ALDOSTERONE SECRETION. ROLE OF THE KIDNEY AND THE RENIN-ANGIOTENSIN SYSTEM (HYPERTENSIN)].
MILLS LF; HAMILTON PM
Annee Endocrinol; 1963; 15():21-6. PubMed ID: 14333522
[No Abstract] [Full Text] [Related]
15. [ON THE IMPORTANCE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PATHOGENESIS OF RENAL HYPERTENSION].
BOGATZKI M
Med Klin; 1964 Jun; 59():1046-8. PubMed ID: 14243291
[No Abstract] [Full Text] [Related]
16. NORMAL AND ALTERED FUNCTION OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN MAN: APPLICATIONS IN CLINICAL AND RESEARCH MEDICINE.
CONN JW; ROVNER DR; COHEN EL
Ann Intern Med; 1965 Aug; 63():266-84. PubMed ID: 14318467
[No Abstract] [Full Text] [Related]
17. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
18. [Possibilities of laboratory diagnosis in the assessment of the activity of the renin-angiotensin-aldosterone system].
Maksimov ML
Ter Arkh; 2010; 82(6):77-80, inside back cover. PubMed ID: 20731118
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.
Epstein M; Reaven NL; Funk SE; McGaughey KJ; Oestreicher N; Knispel J
Am J Manag Care; 2015 Sep; 21(11 Suppl):S212-20. PubMed ID: 26619183
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease.
Gupta G; Dahiya R; Singh Y; Mishra A; Verma A; Gothwal SK; Aljabali AAA; Dureja H; Prasher P; Negi P; Kapoor DN; Goyal R; Tambuwala MM; Chellappan DK; Dua K
Chem Biol Interact; 2020 Feb; 317():108975. PubMed ID: 32032593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
